When research becomes practice: the concept of the therapeutic misconception and challenges to consent in clinical trials.
adaptive clinical trial
clinical trial
informed consent
research ethics
therapeutic misconception
therapeutic misestimation
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
30
09
2022
accepted:
13
12
2022
entrez:
23
2
2023
pubmed:
24
2
2023
medline:
3
3
2023
Statut:
ppublish
Résumé
Many factors influence patients' decisions to participate in clinical trials. For many, the primary motivation is the possibility that they might derive some benefit from participation. This is particularly true for patients with limited treatment options, such as patients with advanced cancer. While this is not surprising, it is potentially problematic if patients fail to recognise the distinction between research and clinical care (a phenomenon known as the 'therapeutic misconception'). This is becoming increasingly problematic as clinical trial designs become more complex, as clinical trials become more embedded in routine clinical care, and as trials are increasingly used by patients and clinicians to access new diagnostic platforms and therapies. We outline some of these recent trends, focusing on the cancer clinical trials landscape as this provides a good case study of the phenomenon. We conclude by making preliminary suggestions that changes to the consent process, perhaps using 'dynamic consent' platforms, might help to mitigate the therapeutic misconception and note the need for further research to guide strategies for improving communication and decision-making.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
271-274Informations de copyright
© 2023 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.
Références
Reeder-Hayes KE, Roberts MC, Henderson GE, Dees EC. Informed consent and decision making among participants in novel-design phase I oncology trials. J Oncol Pract 2017; 13: e863-e73.
Escritt K, Mann M, Nelson A, Harrop E. Hope and meaning-making in phase 1 oncology trials: a systematic review and thematic synthesis of qualitative evidence on patient-participant experiences. Trials 2022; 23: 409.
Pentz RD, White M, Harvey RD, Farmer ZL, Liu Y, Lewis C et al. Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials. Cancer 2012; 118: 4571-8.
Abernethy ER, Campbell GP, Hianik RS, Thomson MC, Blee SM, Sibold HC et al. Reassessing the measurement and presence of therapeutic misconception in a phase 1 setting. Cancer 2021; 127: 3794-800.
Miller FG, Brody H. A critique of clinical equipoise: therapeutic misconception in the ethics of clinical trials. Hastings Cent Rep 2003; 33: 19-28.
Engelbak Nielsen Z, Eriksson S, Schram Harsløf LB, Petri S, Helgesson G, Mangset M et al. Are cancer patients better off if they participate in clinical trials? A mixed methods study. BMC Cancer 2020; 20: 401.
Appelbaum PS, Roth LH, Lidz C. The therapeutic misconception: informed consent in psychiatric research. Int J Law Psychiatry 1982; 5: 319-29.
Henderson GE, Churchill LR, Davis AM, Easter MM, Grady C, Joffe S et al. Clinical trials and medical care: defining the therapeutic misconception. PLoS Med 2007; 4: e324.
Appelbaum PS, Lidz CW. The therapeutic misconception. In: Emanuel EJ, Grady CC, Crouch RA, Lie RK, Miller FG and Wendler DD, eds The Oxford Textbook of Clinical Research Ethics. New York: Oxford University Press; 2008; 633-44.
Horng S, Grady C. Misunderstanding in clinical research: distinguishing therapeutic misconception, therapeutic misestimation, & therapeutic optimism. IRB 2003; 25: 11-6.
Sisk BA, Kodish E. Therapeutic misperceptions in early-phase cancer trials: from categorical to continuous. IRB 2018; 40: 13-20.
Appelbaum PS. Assessment of patients' competence to consent to treatment. N Engl J Med 2007; 357: 1834-40.
Christopher PP, Appelbaum PS, Truong D, Albert K, Maranda L, Lidz C. Reducing therapeutic misconception: a randomized intervention trial in hypothetical clinical trials. PloS One 2017; 12: e0184224.
Abola MV, Prasad V. The use of superlatives in cancer research. JAMA Oncol 2016; 2: 139-41.
Gota V, Nookala M, Yadav A, Menezes SR, Kannan S, Ali R. Quality of informed consent in cancer clinical trials in India: a cross-sectional survey. Natl Med J India 2018; 31: 334-8.
Malan T, Moodley K. Phase 3 oncology clinical trials in South Africa: experimentation or therapeutic misconception? J Empir Res Hum Res Ethics 2016; 11: 47-56.
Godskesen T, Nygren P, Nordin K, Hansson M, Kihlbom U. Phase 1 clinical trials in end-stage cancer: patient understanding of trial premises and motives for participation. Support Care Cancer 2013; 21: 3137-42.
Jansen LA. The optimistic bias and illusions of control in clinical research. IRB 2016; 38: 8-14.
Jansen LA, Mahadevan D, Appelbaum PS, Klein WM, Weinstein ND, Mori M et al. Dispositional optimism and therapeutic expectations in early-phase oncology trials. Cancer 2016; 122: 1238-46.
Weinfurt KP, Sulmasy DP, Schulman KA, Meropol NJ. Patient expectations of benefit from phase I clinical trials: linguistic considerations in diagnosing a therapeutic misconception. Theor Med Bioeth 2003; 24: 329-44.
Sydes MR, Parmar MKB, Mason MD, Clarke NW, Amos C, Anderson J et al. Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials 2012; 13: 168.
Wang H, Yee D. I-SPY 2: a neoadjuvant adaptive clinical trial designed to improve outcomes in high-risk breast cancer. Curr Breast Cancer Rep 2019; 11: 303-10.
Weber JS, Levit LA, Adamson PC, Bruinooge S, Burris HA, Carducci MA et al. American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment. J Clin Oncol 2015; 33: 278-84.
Benjamin DM, Mandel DR, Barnes T, Krzyzanowska MK, Leighl N, Tannock IF et al. Can oncologists predict the efficacy of treatments in randomized trials? Oncologist 2020; 26: 56-62.
Beardsley E, Jefford M, Mileshkin L. Longer consent forms for clinical trials compromise patient understanding: so why are they lengthening? J Clin Oncol 2007; 25: e13-4.
Goncharov L, Suominen H, Cook M. Dynamic consent and personalised medicine. Med J Aust 2022; 216: 547-9.
Haas MA, Teare H, Prictor M, Ceregra G, Vidgen ME, Bunker D et al. ‘CTRL’: an online, dynamic consent and participant engagement platform working towards solving the complexities of consent in genomic research. Eur J Hum Genet 2021; 29: 687-98.